ملخص
Infection with the hepatitis C virus (HCV) is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic. Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.
اللغة الأصلية | English |
---|---|
الصفحات (من إلى) | 312-317 |
عدد الصفحات | 6 |
دورية | Sultan Qaboos University Medical Journal |
مستوى الصوت | 10 |
رقم الإصدار | 3 |
حالة النشر | Published - ديسمبر 2010 |
ASJC Scopus subject areas
- ???subjectarea.asjc.2700.2700???